Fig. 4: Mobility changes of endogenous HER2 on the surface of BT-474 cells (labeled via the affibody ZHER2) upon treatment with DARPins and mAbs as quantified by FRAP.
From: Apoptosis-inducing anti-HER2 agents operate through oligomerization-induced receptor immobilization
a Dramatic loss of mobility upon treatment with bipDARPin 6L1G compared to untreated cells (Untr.). b Concentration dependence of the mobility reduction as illustrated by the relative fluorescence recovery after 48 s. c Homo-bivalent, monoparatopic DARPins 6L46 and GL4G reduce HER2 mobility only slightly, while a mixture of both (GL4G + 6L46) fully immobilizes HER2 through crosslinking. d Similarly, moderate mobility changes are observed upon treatment with therapeutic mAbs PZB and TZB but almost complete immobilization by their combination (PZB + TZB).
